INDP Share Price Performance
Recent INDP News & Updates
No updates
Indaptus Therapeutics, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -27.50
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
Indaptus Therapeutics, Inc. Competitors
About INDP
- Founded
- n/a
- Employees
- 7
- CEO
- WebsiteView website
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.
U.S. Market Performance
- 7 Days: -2.7%
- 3 Months: 10.1%
- 1 Year: 17.7%
- Year to Date: 5.9%
In the last week, the market has been flat, with a notable exception in the Healthcare sector dropping 4.2%. As for the longer term, the market has risen 17% in the past 12 months. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading